Resolvin E1 selectively interacts with leukotriene B4 receptor BLT1 and ChemR23 to regulate inflammation - PubMed (original) (raw)
Clinical Trial
. 2007 Mar 15;178(6):3912-7.
doi: 10.4049/jimmunol.178.6.3912.
Affiliations
- PMID: 17339491
- DOI: 10.4049/jimmunol.178.6.3912
Clinical Trial
Resolvin E1 selectively interacts with leukotriene B4 receptor BLT1 and ChemR23 to regulate inflammation
Makoto Arita et al. J Immunol. 2007.
Abstract
Resolvin E1 (RvE1) is a potent anti-inflammatory and proresolving mediator derived from omega-3 eicosapentaenoic acid generated during the resolution phase of inflammation. RvE1 possesses a unique structure and counterregulatory actions that stop human polymorphonuclear leukocyte (PMN) transendothelial migration and PMN infiltration in several murine inflammatory models. To examine the mechanism(s) underlying anti-inflammatory actions on PMNs, we prepared [(3)H]RvE1 and characterized its interactions with human PMN. Results with membrane fractions of human PMN demonstrated specific binding with a K(d) of 48.3 nM. [(3)H]RvE1 specific binding to human PMN was displaced by leukotriene B(4) (LTB(4)) and LTB(4) receptor 1 (BLT1) antagonist U-75302, but not by chemerin peptide, a ligand specific for another RvE1 receptor ChemR23. Recombinant human BLT1 gave specific binding with [(3)H]RvE1 with a K(d) of 45 nM. RvE1 selectively inhibited adenylate cyclase with BLT1, but not with BLT2. In human PBMC, RvE1 partially induced calcium mobilization, and blocked subsequent stimulation by LTB(4). RvE1 also attenuated LTB(4)-induced NF-kappaB activation in BLT1-transfected cells. In vivo anti-inflammatory actions of RvE1 were sharply reduced in BLT1 knockout mice when given at low doses (100 ng i.v.) in peritonitis. In contrast, RvE1 at higher doses (1.0 mug i.v.) significantly reduced PMN infiltration in a BLT1-independent manner. These results indicate that RvE1 binds to BLT1 as a partial agonist, potentially serving as a local damper of BLT1 signals on leukocytes along with other receptors (e.g., ChemR23-mediated counterregulatory actions) to mediate the resolution of inflammation.
Similar articles
- Leukotriene B4/antimicrobial peptide LL-37 proinflammatory circuits are mediated by BLT1 and FPR2/ALX and are counterregulated by lipoxin A4 and resolvin E1.
Wan M, Godson C, Guiry PJ, Agerberth B, Haeggström JZ. Wan M, et al. FASEB J. 2011 May;25(5):1697-705. doi: 10.1096/fj.10-175687. Epub 2011 Feb 9. FASEB J. 2011. PMID: 21307335 - Resolvin E1/E2 ameliorate lipopolysaccharide-induced depression-like behaviors via ChemR23.
Deyama S, Shimoda K, Suzuki H, Ishikawa Y, Ishimura K, Fukuda H, Hitora-Imamura N, Ide S, Satoh M, Kaneda K, Shuto S, Minami M. Deyama S, et al. Psychopharmacology (Berl). 2018 Jan;235(1):329-336. doi: 10.1007/s00213-017-4774-7. Epub 2017 Oct 31. Psychopharmacology (Berl). 2018. PMID: 29090333 - Resolvin E1 promotes mucosal surface clearance of neutrophils: a new paradigm for inflammatory resolution.
Campbell EL, Louis NA, Tomassetti SE, Canny GO, Arita M, Serhan CN, Colgan SP. Campbell EL, et al. FASEB J. 2007 Oct;21(12):3162-70. doi: 10.1096/fj.07-8473com. Epub 2007 May 11. FASEB J. 2007. PMID: 17496159 - BLT1 and BLT2: the leukotriene B(4) receptors.
Tager AM, Luster AD. Tager AM, et al. Prostaglandins Leukot Essent Fatty Acids. 2003 Aug-Sep;69(2-3):123-34. doi: 10.1016/s0952-3278(03)00073-5. Prostaglandins Leukot Essent Fatty Acids. 2003. PMID: 12895595 Review. - Resolvin E1 as a novel agent for the treatment of asthma.
Hisada T, Ishizuka T, Aoki H, Mori M. Hisada T, et al. Expert Opin Ther Targets. 2009 May;13(5):513-22. doi: 10.1517/14728220902865622. Expert Opin Ther Targets. 2009. PMID: 19368495 Review.
Cited by
- Resolvins in Periodontitis and Possible Periodontal Regeneration: A Literature Review.
Chiluveru S, Gundelly M, Pusuluri SV, Tummanepally M, Chandaka M, Koduganti RR. Chiluveru S, et al. Cureus. 2024 Aug 30;16(8):e68187. doi: 10.7759/cureus.68187. eCollection 2024 Aug. Cureus. 2024. PMID: 39347277 Free PMC article. Review. - Role and mechanism of specialized pro-resolving mediators in obesity-associated insulin resistance.
Liu X, Tang Y, Luo Y, Gao Y, He L. Liu X, et al. Lipids Health Dis. 2024 Jul 30;23(1):234. doi: 10.1186/s12944-024-02207-9. Lipids Health Dis. 2024. PMID: 39080624 Free PMC article. Review. - Lipid mediators in neutrophil biology: inflammation, resolution and beyond.
Ghodsi A, Hidalgo A, Libreros S. Ghodsi A, et al. Curr Opin Hematol. 2024 Jul 1;31(4):175-192. doi: 10.1097/MOH.0000000000000822. Epub 2024 May 7. Curr Opin Hematol. 2024. PMID: 38727155 Review. - Cellular and Molecular Effects of Microgravity on the Immune System: A Focus on Bioactive Lipids.
Fava M, De Dominicis N, Forte G, Bari M, Leuti A, Maccarrone M. Fava M, et al. Biomolecules. 2024 Apr 5;14(4):446. doi: 10.3390/biom14040446. Biomolecules. 2024. PMID: 38672462 Free PMC article. Review. - Targeting immune cell recruitment in atherosclerosis.
Döring Y, van der Vorst EPC, Weber C. Döring Y, et al. Nat Rev Cardiol. 2024 Apr 25. doi: 10.1038/s41569-024-01023-z. Online ahead of print. Nat Rev Cardiol. 2024. PMID: 38664575 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Miscellaneous